Announcement pursuant to regulation 30 of SEBI (Listing Obligation and Disclosure Requirements)Regulation, 2015 regarding launch of new products
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Royal Sense Limited has announced the launch of 9 new products in the pharmaceuticals category, available for sale from 3rd April 2025. The launches include 7 pharma formulations — antifungals (IETRACON 100mg and 200mg), a GERD/acid reflux combination (Isompra DSR), an antibiotic (ILEVOFLOXA 500mg), an amoxicillin-clavulanate combination (Ugmntin LB), a constipation syrup (Pecolux Syrup), and an anti-allergy syrup (JCZ-M Syrup). Additionally, 2 orthopedic support devices were launched — Stergic Next Ankle Binder and Stergic Cervical Neck Support. All products will be sold in the domestic Indian market only, with no international expansion indicated.
The launch expands Royal Sense's product portfolio across therapeutics and ortho-care, which could support future revenue growth if the products gain market traction. However, no revenue guidance, order pipeline, or financial impact has been disclosed, and the products cater only to the domestic market, limiting near-term scale.